The OUD Cascade of Care and Critical Outcomes: Longitudinal Linkage with Opioid Use
OUD 护理和关键成果级联:与阿片类药物使用的纵向联系
基本信息
- 批准号:10741268
- 负责人:
- 金额:$ 71.07万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-06-15 至 2028-03-31
- 项目状态:未结题
- 来源:
- 关键词:AccountingAddressAftercareAttenuatedBuprenorphineCaringCessation of lifeCharacteristicsClinicalCommunitiesDataData SetDatabasesDevelopmentDisease remissionDropsDrug ControlsDrug usageElectronic Health RecordEmergency department visitExposure toFentanylForce of GravityGeographyGoalsHarm ReductionHealth systemHealthcareIllicit DrugsImprove AccessIndividualIntakeKnowledgeLinkLiteratureLong-Term CareMeasurementMeasuresMedicaidModelingOpioidOpioid agonistOutcomeOverdosePathway interactionsPatient DischargePatient riskPatientsPatternPenetrationPharmaceutical PreparationsPharmacotherapyPoliciesPopulationPredictive FactorPrevalencePrognosisProviderPublic HealthRecording of previous eventsRecordsResearchRiskRisk EstimateRisk ReductionRoleService provisionSingle-Payer SystemSiteSystemTest ResultTimeToxicologyaddictionadverse event riskadverse outcomebuprenorphine treatmentcare episodeclinical careclinical decision supportclinical practicedemographicsdesigndrug testingevidence baseexperiencefentanyl exposureimprovedimproved outcomeindexingindividual patientinsurance claimslongitudinal analysismortalitymortality riskopioid epidemicopioid useopioid use disorderoverdose deathoverdose riskpatient populationpatient retentionpersonalized approachprognostic significanceprotective effectpsychostimulantresearch clinical testingrisk stratificationsupport toolstreatment as usualtreatment durationtreatment response
项目摘要
The OUD Cascade of Care and Critical Outcomes: Longitudinal Linkage with Drug Use
Dramatic increases in overdose deaths in the US have created an urgent need to improve access to
and retention in evidence-based care for opioid use disorder (OUD) with medication (MOUD), under the OUD
Cascade of Care framework. The Cascade model emphasizes key stages or transitions during the treatment of
individuals with OUD to reduce risks of adverse outcomes: critically, successful MOUD initiation and long-term
retention. However, it has thus far been agnostic towards concurrent opioid use. In the era of rising fentanyl
prevalence in the illicit drug supply, public health frameworks need to adjust for environmental conditions that
may impact clinical outcomes. Our research approach draws from a conceptualization of opioid use, treatment
response, and adverse outcomes as evolving along trajectories, over varying timeframes emphasizing the
need for harm reduction approaches tailored to patient goals as they evolve over time. While we hypothesize
that greater exposure to fentanyl in the local drug supply will impede successful treatment engagement, we
also expect longer durations of buprenorphine treatment to protect against overdose risk, even among patients
with intermittent opioid use while in care. However, patients with opioid use in care will likely experience
attenuated risk reductions following treatment discontinuation.
There is a critical need for longitudinal analyses of treatment pathways and outcomes, including the
intersecting roles and prognostic significance of toxicology results and treatment retention, and their
relationship to overdose risk during and following treatment. Because current evidence concerning optimal
durations of care, especially at the individual patient or sub-population level, is lacking, there is currently little
empirical evidence to guide clinicians and health systems regarding how to best tailor service provision and
estimate risks of adverse events at the patient level. Our proposal seeks to fill these critical gaps in knowledge.
We will link EHR records for 95,000 individuals from a multi-state buprenorphine provider-- the nation’s
largest OBOT provider-- with Medicaid claims and National Death Index (NDI) data to create a new, unique,
integrated database spanning 2014-2022 in a dozen states to observe patients before intake, at baseline, and
while in care over multiple years, accounting for mortality during the onslaught of fentanyl. Medicaid is now the
largest payer for MOUD. Our findings will have broad implications for clinical care, policy, systems design,
quality measurement development, and healthcare administration. Our goal is to establish an empirical
evidence base to inform clinical evaluations of patient risks (e.g. adverse outcomes including overdose) at the
individual level. Against the scale and gravity of the evolving opioid epidemic, it is vital that clinical and policy
strategies are informed by careful consideration of rigorous analyses of empirical data with large, usual-care
populations across state lines.
护理和关键结局的OUD级联:与药物使用的纵向联系
美国过量死亡人数的急剧增加迫切需要改善获得
阿片类药物使用障碍(OUD)与药物(MOUD)的循证护理,根据OUD
护理级联框架。级联模型强调治疗过程中的关键阶段或过渡,
OUD患者,以降低不良结局的风险:关键,成功的MOUD启动和长期
潴留然而,迄今为止,它对同时使用阿片类药物持不可知论态度。在芬太尼价格上涨的时代
鉴于非法药物供应的普遍性,公共卫生框架需要根据环境条件进行调整,
可能影响临床结果。我们的研究方法来自阿片类药物使用的概念化,
反应,和不良后果,作为演变沿着轨迹,在不同的时间框架,强调
需要针对患者目标定制的伤害减少方法,因为它们随着时间的推移而演变。我们假设
在当地药物供应中更多地接触芬太尼将阻碍成功的治疗参与,我们
我还预计丁丙诺啡治疗的持续时间更长,以防止过量的风险,即使在患者中,
间歇性使用阿片类药物然而,在护理中使用阿片类药物的患者可能会经历
治疗中止后风险降低减弱。
迫切需要对治疗途径和结果进行纵向分析,包括
毒理学结果和治疗保留的交叉作用和预后意义,及其
与治疗期间和治疗后用药过量风险的关系。因为目前的证据表明,
由于缺乏持续的护理,特别是在个别患者或亚群体水平上,目前几乎没有
经验证据,指导临床医生和卫生系统如何最好地定制服务提供,
在患者层面估计不良事件的风险。我们的建议旨在填补这些关键的知识空白。
我们将链接来自多州丁丙诺啡供应商的95,000人的EHR记录-全国最大的丁丙诺啡供应商
最大的OBOT提供商-与医疗补助索赔和国家死亡指数(NDI)数据,以创建一个新的,独特的,
2014年至2022年在十几个州建立的综合数据库,以在摄入前、基线时观察患者,
而在照顾多年,占死亡率在芬太尼的冲击。医疗补助现在是
MOUD的最大付款人。我们的发现将对临床护理、政策、系统设计,
质量测量开发和医疗保健管理。我们的目标是建立一个经验主义的
为患者风险(例如,不良结局,包括用药过量)的临床评价提供信息的证据基础
个人层面。针对不断发展的阿片类药物流行病的规模和严重性,临床和政策至关重要。
战略是通过仔细考虑对大量的经验数据进行严格的分析而制定的,
跨越州界的人口。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Arthur R Williams其他文献
Arthur R Williams的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Arthur R Williams', 18)}}的其他基金
Medical Marijuana Program Participation and Changes in Controlled Substance Use
医用大麻计划的参与和受控物质使用的变化
- 批准号:
9768420 - 财政年份:2018
- 资助金额:
$ 71.07万 - 项目类别:
Improving the treatment cascade of MAT initiation and retention for opioid use disorder
改善阿片类药物使用障碍的 MAT 启动和保留治疗级联
- 批准号:
9982282 - 财政年份:2017
- 资助金额:
$ 71.07万 - 项目类别:
Improving the treatment cascade of MAT initiation and retention for opioid use disorder
改善阿片类药物使用障碍的 MAT 启动和保留治疗级联
- 批准号:
10213680 - 财政年份:2017
- 资助金额:
$ 71.07万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 71.07万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 71.07万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 71.07万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 71.07万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 71.07万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 71.07万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 71.07万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 71.07万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 71.07万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 71.07万 - 项目类别:
Research Grant